Tikcro Technologies

About

Q&A

What is Tikcro Technologies' primary focus?

Tikcro Technologies focuses on leveraging a novel 3D antigen design technology to generate new antibodies that block receptor/ligand surface domains of immune modulators, aiming to re-activate the body's immune system to fight cancer.

What is the current status of Tikcro Technologies?

Tikcro Technologies is currently inactive, having ceased operations in May 2021.

Where is Tikcro Technologies headquartered?

Tikcro Technologies is headquartered in Ness Ziona, Center District, Israel.

When was Tikcro Technologies founded?

Tikcro Technologies was founded in December 1999.

What is the employee count for Tikcro Technologies?

Tikcro Technologies has an employee count in the 1-10 range.

What sector does Tikcro Technologies operate in?

Tikcro Technologies operates primarily in the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.

Has Tikcro Technologies engaged in collaborative research?

Yes, Tikcro Technologies has had extensive collaborative research with the Weizmann Institute of Science in Israel.

Who is the CEO of Tikcro Technologies?

Aviv Boim is the CEO of Tikcro Technologies.

Sectors & technology

Tags